Pharma giants including Novartis collaborate on COVID-19 therapiesA consortium of life sciences companies including pharma giants such as Novartis and Johnson & Johnson, are to Share XPharma giants including Novartis collaborate on COVID-19 therapieshttps://pharmaphorum.com/news/collaborate-covid19-therapies/
Lilly, Galapagos suspend trials as COVID-19 hits health systemsEli Lilly has said it will suspend most clinical trials for the time being in light of the Share XLilly, Galapagos suspend trials as COVID-19 hits health systemshttps://pharmaphorum.com/news/lilly-galapagos-suspend-trials-as-covid-19-hits-health-systems/
Lilly’s CEO warns against medicine hoarding during coronavirus crisisEli Lilly’s CEO has warned against the hoarding of medicines by individual states and countries in the coronavirus Share XLilly’s CEO warns against medicine hoarding during coronavirus crisishttps://pharmaphorum.com/news/lillys-ceo-warns-against-medicine-hoarding-during-coronavirus-crisis/
FDA gives Lilly’s Olumiant breakthrough status for hair lossEli Lilly’s Olumiant is facing tough competition in its approved rheumatoid arthritis indication, but could take the lead Share XFDA gives Lilly’s Olumiant breakthrough status for hair losshttps://pharmaphorum.com/news/fda-gives-lillys-olumiant-breakthrough-status-for-hair-loss/
AbCellera and Eli Lilly join hunt for coronavirus therapyCanadian biotech AbCellera has joined forces with Eli Lilly to co-develop antibody products to prevent and treat COVID-19, Share XAbCellera and Eli Lilly join hunt for coronavirus therapyhttps://pharmaphorum.com/news/abcellera-and-eli-lilly-join-hunt-for-coronavirus-therapy/
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
Pharma staff told to work at home as Biogen deals with coronavirus outbreakThe coronavirus has begun to affect day-to-day operations at pharma companies, with Biogen dealing with an outbreak linked Share XPharma staff told to work at home as Biogen deals with coronavirus outbreakhttps://pharmaphorum.com/news/biogen-deals-with-staff-coronavirus-outbreak/
FDA starts review of Pfizer, Lilly’s non-opioid painkillerAfter years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, Share XFDA starts review of Pfizer, Lilly’s non-opioid painkillerhttps://pharmaphorum.com/news/fda-starts-review-of-pfizer-lillys-non-opioid-painkiller/
CHMP turns down Lilly’s Emgality for cluster headacheAn EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic Share XCHMP turns down Lilly’s Emgality for cluster headachehttps://pharmaphorum.com/news/chmp-turns-down-lillys-emgality-for-cluster-headache/
